1577 related articles for article (PubMed ID: 25987260)
1. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
2. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
3. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
[TBL] [Abstract][Full Text] [Related]
4. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
[TBL] [Abstract][Full Text] [Related]
5. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
[TBL] [Abstract][Full Text] [Related]
6. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
8. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
9. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
[TBL] [Abstract][Full Text] [Related]
10. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Ruilope LM; Segura J
Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Evans M; Bain SC; Hogan S; Bilous RW;
Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
15. Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Doggrell SA
Expert Opin Pharmacother; 2002 May; 3(5):625-8. PubMed ID: 11996640
[TBL] [Abstract][Full Text] [Related]
16. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
[TBL] [Abstract][Full Text] [Related]
17. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
19. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
20. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]